Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/178809
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLidón Gil, Laia-
dc.contributor.authorLlaó Hierro, Laura-
dc.contributor.authorNuvolone, Mario-
dc.contributor.authorAguzzi, Adriano-
dc.contributor.authorÁvila, Jesús-
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)-
dc.contributor.authorRío Fernández, José Antonio del-
dc.contributor.authorGavín Marín, Rosalina-
dc.date.accessioned2021-07-05T09:32:43Z-
dc.date.available2021-07-05T09:32:43Z-
dc.date.issued2021-05-20-
dc.identifier.urihttp://hdl.handle.net/2445/178809-
dc.description.abstractTau protein is largely responsible for tauopathies, including Alzheimer's disease (AD), where it accumulates in the brain as insoluble aggregates. Tau mRNA is regulated by alternative splicing, and inclusion or exclusion of exon 10 gives rise to the 3R and 4R isoforms respectively, whose balance is physiologically regulated. In this sense, one of the several factors that regulate alternative splicing of tau is GSK3β, whose activity is inhibited by the cellular prion protein (PrPC), which has different physiological functions in neuroprotection and neuronal differentiation. Moreover, a relationship between PrPC and tau expression levels has been reported during AD evolution. For this reason, in this study we aimed to analyze the role of PrPC and the implication of GSK3β in the regulation of tau exon 10 alternative splicing. We used AD human samples and mouse models of PrPC ablation and tau overexpression. In addition, we used primary neuronal cultures to develop functional studies. Our results revealed a paralleled association between PrPC expression and tau 4R isoforms in all models analyzed. In this sense, reduction or ablation of PrPC levels induces an increase in tau 3R/4R balance. More relevantly, our data points to GSK3β activity downstream from PrPC in this phenomenon. Our results indicate that PrPC plays a role in tau exon 10 inclusion through the inhibitory capacity of GSK3β.-
dc.format.extent24 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms22105370-
dc.relation.ispartofInternational Journal of Molecular Sciences, 2021, vol. 22, num. 10, p. 5370-
dc.relation.urihttps://doi.org/10.3390/ijms22105370-
dc.rightscc by (c) Lidón Gil, Laia et al., 2021-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationMalalties neurodegeneratives-
dc.subject.classificationMalaltia d'Alzheimer-
dc.subject.classificationMalalties per prions-
dc.subject.otherNeurodegenerative Diseases-
dc.subject.otherAlzheimer's disease-
dc.subject.otherPrion diseases-
dc.titleTau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity-
dc.typeinfo:eu-repo/semantics/article-
dc.date.updated2021-07-02T10:05:19Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid34065232-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut de Neurociències (UBNeuro))
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
ijms-22-05370.pdf4 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons